These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9821228)

  • 1. [Lipanor treatment of atherogenic hyperlipoproteinemia].
    Susekov AV; Tvorogova MG; Arabidze GG; Kukharchuk VV
    Ter Arkh; 1998; 70(9):57-61. PubMed ID: 9821228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].
    Ceska R; Kvasnicka T; Haas T; Soska V; Vaverková H
    Vnitr Lek; 2000 Mar; 46(3):157-60. PubMed ID: 11048518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M; Frohlich J
    Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
    Kukharchuk VV; Rozhkova TA; Kotova LA; Tvorogova MG; Semenova OA
    Ter Arkh; 1996; 68(6):58-61. PubMed ID: 8771689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
    Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of lovastatin therapy on the dynamics of the clinical state of patients with ischemic heart disease and hyperlipoproteinemia].
    Zhukova IM; Iurenev AP; Pomerantsev EV; Martynov AA; Shabalkin BV; Titov VN; Shimbaeva NA; Kotkina AA; Bochkova EI; Lediashova GA
    Ter Arkh; 1990; 62(8):130-3. PubMed ID: 2274859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effectiveness of the hypolipemic preparation lovastatin in patients with ischemic heart disease and hyperlipoproteinemia].
    Iurenev AP; Zhukova IM; Lediashova GA; Kiseleva OA; Pomerantsev EV
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1989; 12(2):71-4. PubMed ID: 2604892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA; Rodríguez-Roa E; Nagy E; Mijares ME; Rodríguez-Larralde A; Gil A; Lundberg U; Carvajal Z; Castillo L; Arocha-Piñango CL
    Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic].
    Ceska R; Stulc T
    Cas Lek Cesk; 2000 Jun; 139(12):369-73. PubMed ID: 10953407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
    Artery; 1980; 8(6):537-46. PubMed ID: 6114725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
    Zhao XQ; Morse JS; Dowdy AA; Heise N; DeAngelis D; Frohlich J; Chait A; Albers JJ; Brown BG
    Am J Cardiol; 2004 Feb; 93(3):307-12. PubMed ID: 14759379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W; Holm E
    Fortschr Med; 1986 Apr; 104(13):280-2. PubMed ID: 3699655
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Bruneder H; Klein HJ
    Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia].
    Tvorogova MG; Lupanov VP; Nuraliev EIu; Zaĭtseva TM; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(8):17-21. PubMed ID: 9770737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.